RepliCel Life Sciences is a biotechnology company headquartered in the rapidly emerging lifesciences hub in Vancouver, Canada specializing in the rapidly growing biotechnology segment called cell therapy.
RepliCel has three large-market cell-based regenerative products in clinical development. These cell therapy products are in development to treat male and female hair loss due to androgenic alopecia, skin aging due to the loss of collagen-based tissue under the skin, and chronic pain and loss of function due to tendinopathy of the ankle, knee, elbow, and shoulder. RepliCel’s cell therapies have all been proven safe in randomized, placebo-controlled phase 1 studies and its lead product, RCH-01 for androgenetic alopecia, is now in pivotal clinical study demonstrating efficacy in restoring hair growth. These cell therapies have been tested in over 100 patients in four countries and cleared for clinical testing by three different regulatory agencies.
RepliCel has also developed a next-generation electronic dermal injector, DermaPrecise, for the injection of products into the skin and subcutaneous tissue which require or would benefit from a high level of consistency and control over depth, dose, and the pressure involved in delivery. DermaPrecise is capable of effective and precise injection of highly viscous products. For the injection of cells which are highly susceptible to pressure capable of damaging them during the injection process, DermaPrecise’s consistent precision removes concerns related to the pressures of mechanical injections or the potential variability of manual injections.
RepliCel is built to be a highly cost-effective virtual technology development organization driving value through long-standing contractual service relationships (research institutions, contract development/manufacturing organizations, clinical research organizations, etc) and strategic commercialization partners who are also invested in the company.
Near-term value inflection milestones for RepliCel investors include the commercial approval and launch of DermaPrecise and the completion of pivotal clinical studies in as a precursor to commercial launch of all three of RepliCel’s cell therapy products in Japan under their unique pathways for expedited market approval.
Here you can keep up-to-date with our share price, upcoming events, and latest presentations. We invite you to sign up for our email alerts and welcome any questions you may have.
|52 Week Low||N/A|
|52 Week High||N/A|
- 1 mo
- 3 mo
- 6 mo
- 1 yr
- 2 yr
- 5 yr
REPCF Market Data
||RepliCel Life Sciences, Inc.|
|Shares Issued on a Fully Diluted Basis||34,252,331|
|ISIN #||CA 76027P1036|
|Fiscal Year End||December 31|
|Date of Incorporation||2010 (RepliCel); 2006 (Trichoscience Innovations, now a RepliCel subsidiary);|
1967 (IPO of original public company into which RepliCel was merged)
|Incorporated||British Columbia, Canada|
|Corporate Attorneys||Clark Wilson LLP|
|Auditors||BDO Canada LLP|